This Article Full Text (PDF) All Versions of this Article: 1074248408320278v1 13/3/226    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hale, S. L. Articles by Kloner, R. A. Search for Related Content PubMed PubMed Citation Articles by Hale, S. L. Articles by Kloner, R. A. Social Bookmarking                         What's this?

The Antianginal Agent, Ranolazine, Reduces Myocardial Infarct Size but Does Not Alter Anatomic No-Reflow or Regional Myocardial Blood Flow in Ischemia/Reperfusion in the Rabbit

Heart Institute, Good Samaritan Hospital and the Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, sharon.hale{at}netscape.com

Robert A. Kloner, MD, PhD, FACC

Heart Institute, Good Samaritan Hospital and the Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California

It has been suggested that ranolazine protects the ischemic/reperfused heart by reducing diastolic wall pressure during ischemia. However, there is limited information regarding the effect of ranolazine on the anatomic zone of no-flow in a model of acute myocardial occlusion/reperfusion. Before coronary artery occlusion (CAO), open-chest anesthetized rabbits were assigned to vehicle or ranolazine. Hearts received 60 minutes of CAO and 3 hours reperfusion. Ischemic risk zone was comparable in the 2 groups. Ranolazine significantly reduced infarct size. There was a non-significant trend for the no-reflow defect to be smaller in the ranolazine group. Regional myocardial blood flow was similar in both groups in the risk zone during ischemia and at 3 hours reperfusion. Heart rates were similar in both groups, whereas mean arterial pressure was reduced in the ranolazine group. While ranolazine was effective in reducing myocardial infarct size, the mechanism by which it did this was independent of improving perfusion during either ischemia or reperfusion, suggesting that ranolazine's effect of reducing infarct size involves alternative mechanisms.

Key Words: ranolazine • infarct size • no-reflow • regional myocardial blood flow • rabbit

This version was published on September 1, 2008

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 3, 226-232 (2008)
DOI: 10.1177/1074248408320278


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. J. Klocke Ranolazine and the Myocardial Demand-Supply Balance J. Am. Coll. Cardiol. Img., November 1, 2009; 2(11): 1310 - 1312. [Full Text] [PDF]

				A. K. Dhalla, W.-Q. Wang, J. Dow, J. C. Shryock, L. Belardinelli, A. Bhandari, and R. A. Kloner Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1923 - H1929. [Abstract] [Full Text] [PDF]